Orgenesis (ORGS) Competitors $0.11 -0.78 (-87.64%) As of 11:14 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. GTBP, CDT, ENVB, PTIX, AKAN, WINT, SRNE, SLRX, VCNX, and EVFMShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include GT Biopharma (GTBP), CDT Equity (CDT), Enveric Biosciences (ENVB), Atrinsic (PTIX), Akanda (AKAN), Windtree Therapeutics (WINT), Sorrento Therapeutics (SRNE), Salarius Pharmaceuticals (SLRX), Vaccinex (VCNX), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors GT Biopharma CDT Equity Enveric Biosciences Atrinsic Akanda Windtree Therapeutics Sorrento Therapeutics Salarius Pharmaceuticals Vaccinex Evofem Biosciences GT Biopharma (NASDAQ:GTBP) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Which has more volatility and risk, GTBP or ORGS? GT Biopharma has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Which has preferable earnings & valuation, GTBP or ORGS? GT Biopharma has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$13.16M-$4.07-0.18Orgenesis$662K0.80-$55.36MN/AN/A Do analysts prefer GTBP or ORGS? GT Biopharma currently has a consensus price target of $11.00, suggesting a potential upside of 1,429.90%. Given GT Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe GT Biopharma is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to GTBP or ORGS? In the previous week, GT Biopharma had 6 more articles in the media than Orgenesis. MarketBeat recorded 6 mentions for GT Biopharma and 0 mentions for Orgenesis. GT Biopharma's average media sentiment score of 0.68 beat Orgenesis' score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media. Company Overall Sentiment GT Biopharma Positive Orgenesis Neutral Do institutionals & insiders believe in GTBP or ORGS? 8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 3.4% of GT Biopharma shares are held by company insiders. Comparatively, 5.7% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is GTBP or ORGS more profitable? GT Biopharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -1,804.34% -200.12% Orgenesis -3,827.81%N/A -130.18% SummaryGT Biopharma beats Orgenesis on 8 of the 14 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$528K$985.67M$6.05B$10.34BDividend YieldN/A4.84%5.66%4.69%P/E RatioN/A1.2885.4326.67Price / Sales0.8030.47586.10179.30Price / CashN/A17.6438.3262.20Price / Book-0.027.3112.746.61Net Income-$55.36M-$7.96M$3.30B$275.78M7 Day PerformanceN/A29.49%1.53%-0.40%1 Month PerformanceN/A26.78%8.11%6.38%1 Year Performance-97.12%-7.50%80.06%33.31% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$0.11-87.6%N/A-77.4%$528K$662K0.00150Gap UpGTBPGT Biopharma1.9538 of 5 stars$0.59+1.1%$11.00+1,775.5%-63.7%$2.09MN/A-0.148Analyst ForecastCDTCDT Equity0.1865 of 5 stars$0.68-1.2%N/A-99.6%$2.08MN/A0.003News CoverageAnalyst ForecastStock SplitENVBEnveric Biosciences2.0981 of 5 stars$0.64-2.8%$10.00+1,464.0%-88.8%$2.08MN/A-0.0220Positive NewsAnalyst ForecastGap DownPTIXAtrinsic1.2689 of 5 stars$3.43-17.1%N/A-56.4%$2.02MN/A-0.362Positive NewsGap DownAKANAkanda1.9458 of 5 stars$4.36-8.6%N/A-65.9%$1.99M$836.66K0.00110Positive NewsGap DownHigh Trading VolumeWINTWindtree Therapeutics1.9718 of 5 stars$0.07flat$350.00+519,959.4%-99.6%$1.97MN/A0.0030Gap UpSRNESorrento Therapeutics0.8924 of 5 stars$0.00flatN/A+0.0%$1.93M$60.32M0.00800SLRXSalarius Pharmaceuticals0.7305 of 5 stars$3.67-3.4%N/A-79.5%$1.87MN/A-0.0820Positive NewsGap UpVCNXVaccinex0.755 of 5 stars$0.62-16.2%N/A-71.7%$1.61M$388K-0.0140Gap DownEVFMEvofem Biosciences0.464 of 5 stars$0.01-12.9%N/A+8.2%$1.50M$11.39M-0.02120Gap Up Related Companies and Tools Related Companies GT Biopharma Alternatives CDT Equity Alternatives Enveric Biosciences Alternatives Atrinsic Alternatives Akanda Alternatives Windtree Therapeutics Alternatives Sorrento Therapeutics Alternatives Salarius Pharmaceuticals Alternatives Vaccinex Alternatives Evofem Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsoleteWhen a new chip can run at the speed of light, the game changes. This is the reality of “TF3” — a man-made...The Oxford Club | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
